Optimization of a device for the storage, mixing and delivery of sterilized bone adhesive

开发用于生物粘合剂的无菌储存、混合和受控输送的β原型装置。** 2015年，加拿大报告了47，000例手腕骨折。2010年，治疗手腕骨折的年度总费用估计为1.04亿美元。经皮骨折内固定术是一种提高该间隙手术疗效的方法。由主要申请人Towler领导的一个工程师和临床医生联盟正在通过2016年获得的NSERC/CIHR CHRP资助开发专有的玻璃聚烯烃酸盐骨水泥（GPC）。这些材料是可注射的，粘附于骨，并且可以配制成在骨折部位具有抗菌和成骨作用。然而，与生物粘附剂同等重要的是“三合一”手术装置的开发和优化，其有助于：1.生物粘附剂前体的储存，2.混合均匀，3。由外科医生将其控制性地输送到骨折部位。总的来说，该解决方案（输送装置和生物粘合剂，以下称为“套件”）将提供应用过程的标准化，降低与手术室中生物粘合剂处理不当相关的风险，这直接转化为加拿大医疗保健系统的成本节约成果。该团队由Towler领导，由PDF Alhalawani协助，并与工程（Protodev Canada）和临床领域（Zalzal和Safir博士）的合作者合作，将在Towler临时专利所涵盖的空间内修改alpha原型输送设备。该项目将产生一个测试版设备，具有更好的耐用性，降低复杂性和增加容量，这将扩展其功能。尽管 ** 该设备的预期用途是储存、混合生物粘合剂并将其输送到手术部位，但所采取的步骤本质上不是临床步骤，而是其方法中的基础工程，这可能会导致设备离开诊所进行开发。用于涂层、绝缘和密封应用的胶水和环氧树脂输送等领域。**

The development of a beta-prototype device for the sterilized storage, mixing and controlled delivery of a bioadhesive.**In 2015, there were 47,000 wrist fractures reported in Canada. A 2010 estimate for the total annual cost of treating wrist fractures was $104M. One method postulated for improving surgical outcomes in this space is percutaneous fracture fixation.**A consortia of engineers and clinicians, led by Principal Applicant Towler, are developing proprietary glass polyalkenoate cements (GPCs) through a NSERC/CIHR CHRP grant secured in 2016. These materials are injectable, adhesive to bone and can be formulated to be both antibacterial and osteogenic at the fracture site. However, of equal importance to the bioadhesive is the development and optimization of a '3-in-1' procedural device which facilitates: 1. the storage of the bioadhesive precursors, 2. their uniform mixing and 3. Their controlled delivery by surgeons to the fracture site. Collectively, the solution (the delivery device and the bioadhesive, henceforth known as the 'Kit'), will provide standardization of the application process, reducing risks associated with improper handling of the bioadhesive in operating rooms which directly translates to cost saving outcomes for the Canadian healthcare system.**The team, led by Towler, assisted by PDF Alhalawani and with collaborators from the engineering (Protodev Canada) and clinical fields (Drs. Zalzal and Safir), will amend an alpha prototype delivery device, within the space covered by Towler's provisional patent. The project will yield a beta device with improved durability, reduced complexity and increased capacity, which will expand its functionality. Although the intended use of**the device is to store, mix and deliver the bioadhesive to surgical sites, the steps being taken are not clinical in nature, but fundamental engineering in their approach which may result in a device that leaves the clinic for exploitation in fields such as the delivery of glues and epoxies for coating, insulation and sealing applications.**